Clinical trials: Platelet Reactivity
Symptomatic Aortic Stenosis
Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation
The narrowing of the aortic valve, which prevents blood from reaching the entire body correctly is a common disease in our environment.
- Trial name
- REACTIC-TAVI (NCT04331145)
- Testing
- Ticagrelor 60mg
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Andres Iñiguez Romo
Coronary Artery Disease
Use of a Point-of-Care Platelet Function Assay for the Prediction of Atherothrombotic Events
1. To evaluate the role of VerifyNow test as prognostic marker in routine clinical practice using drug-eluting stents. 2. To determine the add-on-effect of VerifyNow test beyond on conventional risk factors (clinical, lesions, or…
- Trial name
- ASAN-VERIFY (NCT01183754)
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- CardioVascular Research Foundation, Korea
Anaphylaxis, Allergy
Mechanisms of Anaphylaxis
The purpose of this study is to explore different mechanisms for anaphylaxis and find novel biomarkers for this hypersensitivity syndrome.
- Conditions
- Anaphylaxis, Allergy, Transfusion Reaction, Febrile Transfusion Reaction
- Trial name
- ANAMEK (NCT03182491)
- Testing
- Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)
- Where
- Norway
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Platelet Reactivity
High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
This is a prospective, multi-center, non-randomized, controlled study in 2 sequential groups of P2Y12 inhibitor-naive consecutive STEMI patients undergoing primary PCI.
- Trial name
- NCT01835353
- Testing
- Prasugrel 100mg loading dose, Prasugrel 60mg loading dose
- Where
- Greece
- Volunteers
- 82 people
- Sponsor
- University of Patras
Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus
Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus
Prospective, single center, double-blind, randomized pharmacodynamic experimental study. The study will enroll 150 subjects with ASCVD on optimal statin therapy as per physician and Diabetes Mellitus (DM) undergoing elective…
- Conditions
- Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus, Percutaneous Coronary Intervention
- Trial name
- ISS-DMII (NCT03258281)
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Inova Health Care Services
Coronary Artery Disease, Acute Coronary Syndrome
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a third generation thienopyridine, and ticagrelor, a first in class cyclopentyltriazolopyrimidine (CPTP).
- Trial name
- SWAP3 (NCT02016170)
- Testing
- Ticagrelor 180mg, Prasugrel 10mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Florida
PRU, miRNA
The Relationship of Platelet Micro-RNA Expression and Platelet Reactivity in Patients Under Clopidogrel or Ticagrelor Treatment
For acute coronary syndrome patients undergoing cardiac catheterization after stenting, we will give dual antiplatelet drugs (dual antiplatelet agents) therapy, the choice of the basis of medical criteria (clinical guidelines)…
- Trial name
- NCT02101437
- Testing
- miRNA within 24hr, miRNA after 1 week, miRNA after 1 month
- Where
- Taiwan
- Volunteers
- 175 people
- Sponsor
- Taipei City Hospital
Healthy, Transfusion Reactions
Effects of Antibodies to White Blood Cells on Platelet Transfusion Patients
This study will determine if transfusion of platelets containing HLA antibodies (certain antibodies to white blood cells) are more likely to cause transfusion reactions than transfusion of platelets that do not contain HLA…
- Trial name
- NCT00460122
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Peripheral Artery Disease, Clopidogrel, Poor Metabolism of
The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.
- Conditions
- Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease, Artery Disease
- Trial name
- NCT04007055
- Testing
- Point of care screening for HPR, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Marissa Jarosinski
Chronic Kidney Disease
ONSET and OFFSET of Ticagrelor in ESRD
Patients with severe chronic kidney disease or end stage renal disease (ESRD) on hemodialysis (HD) exhibited higher platelet reactivity to clopidogrel than did those with normal renal function.
- Trial name
- NCT02163954
- Testing
- Ticagrelor, Clopidogrel
- Where
- South Korea
- Volunteers
- 16 people
- Sponsor
- Kyunghee University Medical Center
ST-elevation Myocardial Infarction
Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
This is a multi-center, prospective, randomized, single-blind, investigator initiated, pharmacodynamic study of parallel design, performed at 3 institutions (Patras University Hospital; Evangelismos Athens General Hospital…
- Trial name
- NCT01575795
- Testing
- Ticagrelor
- Where
- Greece
- Volunteers
- 83 people
- Sponsor
- University of Patras
Aneurysm, Cerebral, Endovascular Procedures
Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm
Perform a randomized comparison study of dual-antiplatelet (aspirin, prasugrel) and triple-antiplatelet (aspirin, clopidogrel, and cilostazol) preparation using P2Y12 assay in patients with high on-treatment platelet reactivity…
- Trial name
- NCT03581409
- Testing
- Aspirin, Prasugrel, Clopidogrel
- Where
- South Korea
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Thrombosis, Arterial Occlusive Diseases
Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
The goal of this clinical trial is to learn if a blood clotting test called thromboelastography with platelet mapping (TEG-PM) can guide blood-thinning medication decisions in adults more than 60 years and older with peripheral…
- Conditions
- Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD)
- Trial name
- TARGET (NCT07597239)
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Massachusetts General Hospital
Coronary Artery Disease
High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients
Dual antiplatelet therapy with Aspirin and Clopidogrel for at least one year is essential in patients following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) with drug eluting stent(s) implantation.
- Trial name
- TRIPLETE RESET (NCT01543932)
- Testing
- Clopidogrel, Prasugrel, Ticagrelor
- Where
- Italy
- Volunteers
- 81 people
- Sponsor
- University of Roma La Sapienza
Arteriosclerosis, Acute Myocardial Infarction
Menopause Related Influences on Leukocyte Distribution, Monocyte Function and Platelet Reactivity
Women and men show marked differences in cardiovascular risk profile and outcome. Women experience fewer cardiovascular events than men before menopause, but this relationship seems to reverse at menopause.
- Conditions
- Arteriosclerosis, Acute Myocardial Infarction, Cardiovascular Events, Menopause
- Trial name
- NCT05985447
- Where
- Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Coronary Artery Disease
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
The primary objective is to determine the pharmacodynamic effect of ticagrelor dosing (180mg LD/ 90mg BID) at 2, 4 hours and 14 days in stable Coronary artery disease (CAD) patients who exhibit high-on prasugrel platelet…
- Trial name
- HEIGHTEN (NCT01869309)
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- LifeBridge Health
ST-elevation Myocardial Infarction
Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not
This study aims to evaluate the impact on myocardial reperfusion and residual thrombotic burden of adding Cangrelor -a potent and immediate P2Y12 inhibitor- to ticagrelor in primary PCI patients with high on ticagrelor platelet…
- Trial name
- ERMIT (NCT04927949)
- Testing
- cangrelor perfusion during PCI, standard PCI
- Where
- France
- Volunteers
- 128 people
- Sponsor
- University Hospital, Caen
Coronary Artery Disease
Potential Impact of Cigarette Smoking on Platelet Reactivity in Patients on Dual Antiplatelet Therapy With P2Y12 Inhibitors
All consecutive patients undergone PTCA in the period between July 2013 and December 2013 are eligible to be enrolled. Study population are divided in : Group 1: smokers on dual antiplatelet therapy with ASA (100 mg once a day)…
- Trial name
- COPTER (NCT02026713)
- Testing
- quit smoking for a 2 weeks period
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- University of Roma La Sapienza
Heart Disease
Prediction of Bleeding and Transfusion Outcomes and Assessment of Perioperative Platelet Reactivity in Cardiac Surgery
Excessive bleeding after cardiopulmonary bypass (CPB) operations remains to be a persistent problem. Antiplatelet therapy (APT) is an integral component of perioperative management in patients undergoing cardiac surgery.
- Trial name
- NCT02277379
- Where
- Croatia
- Volunteers
- 113 people
- Sponsor
- University of Zagreb
Chronic Kidney Disease, Stable Angina
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease
Impaired renal function is associated with reduced responsiveness to clopidogrel. There are no studies which have shown a means by which to overcome platelet hyporesponsiveness in patients with chronic kidney disease (CKD).
- Trial name
- CKD (NCT01328470)
- Testing
- Clopidogrel, cilostazol
- Where
- South Korea
- Volunteers
- 85 people
- Sponsor
- Kyunghee University Medical Center